alexa Bilateral Bronchiectasis in a 73 Year Old Man | OMICS International
ISSN: 2472-1247
Journal of Clinical Respiratory Diseases and Care
Like us on:
Make the best use of Scientific Research and information from our 700+ peer reviewed, Open Access Journals that operates with the help of 50,000+ Editorial Board Members and esteemed reviewers and 1000+ Scientific associations in Medical, Clinical, Pharmaceutical, Engineering, Technology and Management Fields.
Meet Inspiring Speakers and Experts at our 3000+ Global Conferenceseries Events with over 600+ Conferences, 1200+ Symposiums and 1200+ Workshops on
Medical, Pharma, Engineering, Science, Technology and Business

Bilateral Bronchiectasis in a 73 Year Old Man

Dipti Gothi*

Department of Pulmonary Medicine, ESI, PGIMSR, New Delhi, India

Corresponding Author:
Gothi D
Professor, Department of Pulmonary Medicine, Basaidarapur, Ring Road, ESI, PGIMSR, New Delhi, 110015, India
Tel: +919810080751
Fax: +919810080751
E-mail: [email protected]

Received Date: July 30, 2016; Accepted Date: August 10, 2016; Published Date: August 13, 2016

Citation: Gothi D (2016) Bilateral Bronchiectasis in a 73 Year Old Man. J Clin Respir Dis Care 2:i003. doi: 10.4172/2472-1247.1000i003

Copyright: © 2016 Gothi D. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Visit for more related articles at Journal of Clinical Respiratory Diseases and Care

Clinical Summary

A 73yr old non-smoker man, retired school teacher, was referred for evaluation of breathlessness, cough with copious amount of sputum and intermittent fever of 2 years duration. There were no relevant systemic complaints or significant past history. On examination he had normal vital parameters and coarse crackles in the bilateral infrascapular and infra-axillary region.

The laboratory results showed normal haemogram and serum biochemistry. Enzyme linked immunosorbent assay for human immunodeficiency virus (HIV) was negative. The chest roentgenogram did not show any significant abnormality. He was subjected to high resolution computed tomography (HRCT) of thorax shown in Figure 1. The sputum smear examination for acid fast bacilli was positive.

clinical-respiratory-diseases-care-section-HRCT-thorax

Figure 1: Transverse section of HRCT thorax

Diagnosis

1. What does HRCT thorax show? What are the differential diagnoses on HRCT thorax? What is the most likely diagnosis?

2. What is the classification of non tuberculous mycobacteria (NTM)?

3. What are the radiological manifestations pulmonary NTM?

4. What are tests required to confirm the diagnosis and what would be the final diagnosis if it is positive?

Answers

1. The HRCT thorax shows cystic lesions and nodular branching opacities prominently in the middle, lingular and lower lobes and a small cavity in the right lower lobe. The appearance of branching centrilobular nodules with bronchiectasis is highly suggestive of although not diagnostic of nodular bronchiectatic form of NTM [1]. It may also be seen in panbronchiolitis and bronchiectasis associated with non-specific bronchiolitis. If bronchiolitis with bronchiectasis is present in all the lobes or there is associated lobular consolidation or cavity, NTM pulmonary infection is the most likely diagnosis [1].

2. Runyon devised the first good scheme for grouping based on the growth rate and colony pigmentation [2]. Recently, a more appropriate grouping has been described based on the type of clinical disease they produce: disseminated disease, pulmonary disease, cutaneous disease, and others (eye, mastoid, sinus, breast, meninges, peritoneum, appendix, pericardium, kidney, prostate, bursa, joints, bones, lymph nodes) [3]. Disseminated disease usually occurs in immunocompromised host whereas localized disease i.e. pulmonary, cutaneous & others are reported in immunocompetent host [3].

3. The radiological manifestation of pulmonary NTM has three classic forms: nodular bronchiectasis, upper lobe cavity and hypersensitivity pneumonitis ("hot-tub lung") (Table 1) [4]. The nodular bronchiectatic form of pulmonary infection usually occurs in nonsmoker, middle-aged and elderly individuals without underlying lung disease. The typical HRCT findings of nodular bronchiectatic form of NTM are multiple small centrilobular nodules (<5 mm) with “tree in bud” appearance combined with bronchiectasis in the same lobe of the lung which progress over time [5]. The lesions are observed predominantly in the right middle lobe and lingular segment of the left upper lobe [4]. In contrast to nodular bronchiectatic form, the cavitary form is typically seen in smokers and elderly men with underlying chronic lung disease, usually chronic obstructive pulmonary disease. Though, radiologically the upper lobe cavitary form is similar to post primary pulmonary tuberculosis, clinically it has more indolent course. The pulmonary form of hypersensitivity pneumonitis (HP) is caused by hot tub exposure and is clinically and radiologically similar to HP due to other organisms [6].

  Cavitatory Nodular bronchiectasis Hypersensitivity pneumonitis
Age Middle age Middle age/ elderly Any
Sex Predominantly male Predominently female Any
Underlying lung disease Chronic obstructive pulmonary disease No underlying disease No underlying lung disease
Immunocompetency Immunocompetent Immunocompetent Immunocompetent
Radiological pattern Upper lobe, Cavity, Nodule, similar to classical pulmonary Tuberculosis Middle/Lingular/lower lobe, bronchiectasis, ‘tree in bud’ appearance Ill-defined, ground-glass centrilobular nodules, more diffuse ground-glass opacities, and air trapping on expiratory examination
Progression Slowly progressive Slowly progressive sometimes static Rapidly progressive
Organism MAC, M. kansasii and to a lesser extent by M. xenopi, M. abscessus and M. malomense. Mycobacterium (M) avium-intercellulare complex (MAC), however M. abscessus, M. kansasii and M. fortuitum MAC
Indication of treatment Treatment is required Treatment is indicated only if the disease is progressive Prompt treatment is required
Treatment Daily therapy Azithromycin/Clarithromycin, Ethambutol, Rifampicin Thrice in a week therapy Azithromycin/Clarithromycin, Ethambutol, Rifampicin Cessation of exposure to hot water tubs, corticosteroids, antimycobacterial therapy

Table 1: Clinicoradiological manifestations of Non Tuberculous Mycobacteria.

4. As per the American Thoracic Society (ATS) guidelines it requires clinical features, radiological characteristics and positive cultures on two different occasions to diagnose NTM [7]. The patient had two positive BACTEC cultures and both showed positive Nitro Acetylamino hydroxyl propiophenone (NAP) test. Since the patient was a non-smoker without underlying lung disease with nodular bronchiectatic pattern on HRCT and two positive cultures he was diagnosed to have nodular bronchiectasis form of NTM. The nodular bronchiectatic form is treated only if the disease is progressive, thus he was kept under observation. In this case, since two sputum samples were sent for NTM culture soon after the patient presented, diagnosis was hastened.

Discussion

NTM exist free in nature and are well recognized causes of disease in humans and animals. An assortment of names has been employed to describe these mycobacteria like: anonymous mycobacteria, tuberculoid mycobacteria, atypical mycobacteria, opportunistic mycobacteria and mycobacteria other than tuberculosis. NTM commonly causing pulmonary infection are Mycobacterium (M) avium-intercellulare complex (MAC); M. kansaii; M. abscessus; M. chelonae and M. fortuitum of which MAC is the commonest pathogen [5]. The nodular bronchiectatic form is usually caused by MAC, however M. abscessus, M. kansasii and M. fortuitum are also known to cause the disease [7]. The progression of disease in nodular form is slow and treatment is indicated only if the disease is progressive. The cavitary form of disease is generally caused by MAC, M. kansasii and to a lesser extent by M. xenopi, M. abscessus and M. malomense. It is progressive in nature, and if left untreated can lead to extensive lung destruction and death. HP is commonly associated with MAC. The prognosis is good and prompt resolution of symptoms is expected following treatment [8]. Medical therapy for NTM involves multiple agents to facilitate clearance of organisms and minimize the emergence of drug resistance. Though it is important to identify the species for treatment the cornerstone agents include macrolides, ethambutol, and rifamycin. Patients with nodular bronchiectatic lung disease and those with less severe or indolent infections are effectively managed with a 3-times-weekly regimen that includes clarithromycin 1000 mg or azithromycin 500 mg plus ethambutol 25 mg/kg plus rifampin 10 mg/kg/day (maximum 600 mg/day) [7,9,10]. Intermittent drug therapy is not recommended for patients who have cavitary disease, patients who have been previously treated, or patients who have moderate or severe disease. The treatment is continued until culture is negative on therapy for 1 year. If the disease is progressive in spite of treatment and sufficiently localized and where lung function permits, surgical resection under chemotherapeutic cover is considered. In countries with high prevalence of tuberculosis, this entity needs to be remembered as it can lead to treatment failure [11]. To conclude, high index of suspicion is the key to the diagnosis of NTM infection. Patients with bronchiectasis and nodules on HRCT thorax should be advised a microbiological and culture examination of their sputum for NTM organisms for early diagnosis and appropriate management [12].

References

Select your language of interest to view the total content in your interested language
Post your comment

Share This Article

Relevant Topics

Recommended Conferences

  • Annual Congress on Research and Innovations in Medicine
    July 02-03, 2018 Bangkok, Thailand
  • Global Physicians and Healthcare Congress
    June 25-27, 2018 Dubai, UAE
  • International Conference on Medical and Health Science
    August 24-25, 2018 Tokyo, Japan
  • 8th International Congress on Health and Medicine
    October 08-09, 2018 Osaka, Japan

Article Usage

  • Total views: 8289
  • [From(publication date):
    September-2016 - Feb 25, 2018]
  • Breakdown by view type
  • HTML page views : 8201
  • PDF downloads : 88
 

Post your comment

captcha   Reload  Can't read the image? click here to refresh

Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2018-19
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

Agri & Aquaculture Journals

Dr. Krish

[email protected]

1-702-714-7001Extn: 9040

Biochemistry Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Business & Management Journals

Ronald

[email protected]

1-702-714-7001Extn: 9042

Chemistry Journals

Gabriel Shaw

[email protected]

1-702-714-7001Extn: 9040

Clinical Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Engineering Journals

James Franklin

[email protected]

1-702-714-7001Extn: 9042

Food & Nutrition Journals

Katie Wilson

[email protected]

1-702-714-7001Extn: 9042

General Science

Andrea Jason

[email protected]

1-702-714-7001Extn: 9043

Genetics & Molecular Biology Journals

Anna Melissa

[email protected]

1-702-714-7001Extn: 9006

Immunology & Microbiology Journals

David Gorantl

[email protected]

1-702-714-7001Extn: 9014

Materials Science Journals

Rachle Green

[email protected]

1-702-714-7001Extn: 9039

Nursing & Health Care Journals

Stephanie Skinner

[email protected]

1-702-714-7001Extn: 9039

Medical Journals

Nimmi Anna

[email protected]

1-702-714-7001Extn: 9038

Neuroscience & Psychology Journals

Nathan T

[email protected]

1-702-714-7001Extn: 9041

Pharmaceutical Sciences Journals

Ann Jose

[email protected]

1-702-714-7001Extn: 9007

Social & Political Science Journals

Steve Harry

[email protected]

1-702-714-7001Extn: 9042

 
© 2008- 2018 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version